Jonathan Emberson

• Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.

  Mafham MM. et al, (2017), Nephrol Dial Transplant

• Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care.

  Hin H. et al, (2016), Osteoporos Int

• Are statins useful in patients with advanced chronic kidney disease? - Authors' reply.

  Herrington WG. et al, (2016), Lancet Diabetes Endocrinol, 4, 971 - 972

• Interpretation of the evidence for the efficacy and safety of statin therapy.

  Collins R. et al, (2016), Lancet (London, England)

• Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).

  Staplin N. et al, (2016), American Journal of Kidney Diseases, 68, 371 - 380

• Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials.

  Lees KR. et al, (2016), Stroke, 47, 2373 - 2379

• What are the risks of intracerebral haemorrhage due to alteplase after acute ischaemic stroke? Results from an individual patient data meta-analysis of randomised trials

  Emberson J. and baigent None., (2016), Lancet Neurology

• Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials

  Herrington W. et al, (2016), The Lancet Diabetes and Endocrinology

• Protocol for analyses of adverse event data from randomized controlled trials of statin therapy

  Reith C. et al, (2016), American Heart Journal, 176, 63 - 69

• OC04_04 Extreme Cardiac and Renal Mortality From Diabetes: 12-Year Blood-Based Prospective Study of 150,000 Mexican Adults

  Alegre-Díaz J. et al, (2016), Global Heart, 11, s5 - s5

• Perioperative Rosuvastatin in Cardiac Surgery.

  Zheng Z. et al, (2016), The New England journal of medicine, 374, 1744 - 1753

• Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)

  Mihaylova B. et al, (2016), American Journal of Kidney Diseases

• Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

  Ettehad D. et al, (2016), Lancet, 387, 957 - 967

• Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.

  Morton RL. et al, (2016), Am J Kidney Dis, 67, 31 - 39

• Diabetes and cause-specific mortality: evidence from 55 000 deaths in 700 000 adults in 44 studies from the Prospective Studies Collaboration

  Gnatiuc L. et al, (2015), Diabetologia (2015) 58: 1., 58, S4 - S4

• Prevalence, treatment and control of hypertension in middle-aged Mexican adults

  Gnatiuc L. et al, (2015), Eur Heart J (2015) 36 (suppl 1): 1229-1310, 36, 1185 - 1185

• Lack of effect of higher dose vitamin D supplements on systolic blood pressure and arterial stiffness measure in older people after 12 months of treatment. Results of BEST-D trial

  Tomson J. et al, (2015), EUROPEAN HEART JOURNAL, 36, 801 - 801

• Diabetes and cause-specific mortality: evidence from 55 000 deaths in 700 000 adults in 44 prospective studies

  Gnatiuc L. et al, (2015), Eur Heart J (2015) 36 (suppl 1): 1229-1310, 36, 724 - 724

• Avoidable deaths from cardiovascular diseases: 40-year follow-up of 19,000 London Civil Servants

  Clarke R. et al, (2015), EUROPEAN HEART JOURNAL, 36, 983 - 983

• IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE

  Morton RL. et al, (2015), NEPHROLOGY DIALYSIS TRANSPLANTATION, 30

• Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration

  Pitcher A. et al, (2015), American Heart Journal, 169, 605 - 612

• Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.

  Pitcher A. et al, (2015), Am Heart J, 169, 605 - 612

• What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?

  Kent S. et al, (2015), BMC Nephrol, 16

• Thrombolysis in acute stroke Reply

  Emberson J. et al, (2015), LANCET, 385, 1396 - 1396

• Thrombolysis in acute stroke--authors' reply.

  Emberson J. et al, (2015), Lancet, 385

• Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

  Cholesterol Treatment Trialists' (CTT) Collaboration None. et al, (2015), Lancet, 385, 1397 - 1405

• The effect of delay, age, and stroke severity on the risk of intracranial hemorrhage after intravenous alteplase for acute stroke: An individual patient data meta-analysis

  Whiteley WN. et al, (2015), INTERNATIONAL JOURNAL OF STROKE, 10, 21 - 21

• Estimation of the optimum dose of vitamin D for disease prevention in older people: rationale, design and baseline characteristics of the BEST-D trial.

  Clarke R. et al, (2015), Maturitas, 80, 426 - 431

• Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study.

  Vale CL. et al, (2015), BMJ, 350

• Evidence for the Prevention and Treatment of Stroke in Dialysis Patients

  Herrington W. et al, (2015), Seminars in Dialysis, 28, 35 - 47

• Evidence for the prevention and treatment of stroke in dialysis patients.

  Herrington W. et al, (2015), Semin Dial, 28, 35 - 47

• Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial

  Clarke R. et al, (2015), Maturitas, 80, 426 - 431

• Authors' reply

  Emberson J. et al, (2015), The Lancet, 385

• Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials

  Emberson J. et al, (2014), The Lancet, 384, 1929 - 1935

• Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.

  Emberson J. et al, (2014), Lancet, 384, 1929 - 1935

• Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar.

  Wen CP. et al, (2014), Kidney Int, 86, 819 - 827

• Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data.

  Blood Pressure Lowering Treatment Trialists' Collaboration None. et al, (2014), Lancet, 384, 591 - 598

• Effects of lowering LDL cholesterol on progression of kidney disease.

  Haynes R. et al, (2014), J Am Soc Nephrol, 25, 1825 - 1833

• Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial

  Haynes R. et al, (2014), The Lancet

• Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).

  Haynes R. et al, (2014), Am J Kidney Dis, 64, 40 - 48

• The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.

  Herrington W. et al, (2014), Clin J Am Soc Nephrol, 9, 914 - 919

• Coxibs and traditional NSAIDs for pain relief - Authors' reply.

  Bhala N. et al, (2014), Lancet, 383

• Smoking and risk of vascular and non-vascular mortality in old age: 15-year follow-up of 7000 men in the Whitehall resurvey

  Emberson J. et al, (2013), EUROPEAN HEART JOURNAL, 34, 12 - 12

• Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis.

  Stroke Thrombolysis Trialists' Collaborative Group None., (2013), Int J Stroke, 8, 278 - 283

• Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

  Coxib and traditional NSAID Trialists' (CNT) Collaboration None., (2013), Lancet, Ahead of Print

• Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol.

  Haynes R. et al, (2013), Transplant Res, 2

• Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths.

  Tomson J. et al, (2013), Eur Heart J, 34, 1365 - 1374

• Authors' reply

  Mihaylova B. et al, (2012), The Lancet, 380, 1817 - 1818

• Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials

  Rahimi K. et al, (2012), PLOS MEDICINE, 9

• Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials.

  Rahimi K. et al, (2012), Eur Heart J, 33, 1571 - 1581

• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

  Mihaylova B. et al, (2012), Lancet

• Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate.

  Matsushita K. et al, (2012), JAMA, 307, 1941 - 1951

• Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175,000 people in 27 randomised trials of Statin therapy: Cholesterol Treatment Trialists' (CTT) Collaboration

  De Lemos J. et al, (2012), PLoS ONE, 7

• Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy

  Emberson JR. et al, (2012), PLoS ONE, 7

• Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.

  Cholesterol Treatment Trialists' (CTT) Collaboration None. et al, (2012), PLoS One, 7

• Serum free light chains and the risk of ESRD and death in CKD.

  Haynes R. et al, (2011), Clin J Am Soc Nephrol, 6, 2829 - 2837

• Benefits of lowering cholesterol in chronic kidney disease - Authors' reply

  Baigent C. et al, (2011), The Lancet, 378, 1377 - 1378

• Text messaging in smoking cessation: the txt2stop trial.

  Bennett DA. and Emberson JR., (2011), Lancet, 378, 6 - 7

• The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

  Baigent C. et al, (2011), Lancet, 377, 2181 - 2192

• C-reactive protein in the Heart Protection Study Reply

  Emberson J. et al, (2011), LANCET, 377, 1918 - 1919

• C-reactive protein in the Heart Protection Study - Authors' reply

  Emberson J. et al, (2011), The Lancet, 377, 1918 - 1919

• Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.

  Astor BC. et al, (2011), Kidney Int, 79, 1331 - 1340

• Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials.

  Rahimi K. et al, (2011), BMJ, 342

• Authors' reply

  Baigent C. et al, (2011), The Lancet, 377, 715 - 716

• C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study

  Emberson J. et al, (2011), Lancet, 377, 469 - 476

• Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.

  Mafham M. et al, (2011), PLoS One, 6

• Prediction of ESRD and death among people with CKD: The chronic renal impairment in Birmingham (CRIB) prospective cohort study

  Landray MJ. et al, (2010), American Journal of Kidney Diseases, 56, 1082 - 1094

• Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.

  Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group None. et al, (2010), Lancet, 376, 1658 - 1669

• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

  Cholesterol Treatment Trialists’ (CTT) Collaboration None. et al, (2010), Lancet, 376, 1670 - 1681

• Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

  Baigent C. et al, (2010), AMERICAN HEART JOURNAL, 160, 785 - U28

• Safety of statin therapy: meta-analysis of data on cancer from 166 000 participants in 25 randomised trials

  Emberson J. and Co CTT., (2010), EUROPEAN HEART JOURNAL, 31, 898 - 898

• Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.

  Emberson JR. et al, (2010), J Intern Med, 268, 145 - 154

• Clinical Trials and Meta-Analysis

  Emberson JR. and Baigent C., (2010), 26 - 37

• Stratification for exploring heterogeneity in systematic reviews.

  Bennett DA. and Emberson JR., (2009), Evid Based Med, 14, 162 - 164

• Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients

  Bellomo R. et al, (2009), NEW ENGLAND JOURNAL OF MEDICINE, 361, 1627 - 1638

• ACP Journal Club. Stratification for exploring heterogeneity in systematic reviews.

  Bennett DA. and Emberson JR., (2009), Ann Intern Med, 151, JC4 - JC3

• Life expectancy in relation to cardiovascular risk factors: 38 year follow-up of 19 000 men in the Whitehall study

  Clarke R. et al, (2009), BMJ (Online), 339

• Life expectancy in relation to cardiovascular risk factors: 38 year follow-up of 19,000 men in the Whitehall study.

  Clarke R. et al, (2009), BMJ, 339

• Aspirin in the primary prevention of vascular disease - ATT secretariat's reply

  Baigent C. et al, (2009), The Lancet, 374

• Underestimation of the importance of isolated systolic hypertension in older people

  Clarke R. and Emberson JR., (2009), EUROPEAN HEART JOURNAL, 30, 154 - 154

• Effect of statins on ventricular arrhythmic events: a collaborative meta-analysis of randomised controlled trials

  Rahimi K. et al, (2009), EUROPEAN HEART JOURNAL, 30, 591 - 591

• Effect of statins on atrial fibrillation: a collaborative meta-analysis of randomised controlled trials

  Rahimi K. et al, (2009), EUROPEAN HEART JOURNAL, 30, 450 - 451

• Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

  Antithrombotic Trialists' (ATT) Collaboration None. et al, (2009), Lancet, 373, 1849 - 1860

• Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.

  Prospective Studies Collaboration None. et al, (2009), Lancet, 373, 1083 - 1096

• The prevalence of chronic diseases and major disease risk factors at different ages among 150,000 men and women living in Mexico City: cross-sectional analyses of a prospective study.

  Kuri-Morales P. et al, (2009), BMC Public Health, 9

• Analyses of cancer data from three ezetimibe trials.

  Peto R. et al, (2008), N Engl J Med, 359, 1357 - 1366

• Cystatin-C predicts vascular and non-vascular mortality in older men

  Emberson J. et al, (2008), EUROPEAN HEART JOURNAL, 29, 356 - 356

• Randomization is essential for progress in transplant medicine.

  Baigent C. and Emberson JR., (2008), Transplantation, 86, 26 - 27

• Cholesterol, statins, and mortality - Reply

  Lewington S. et al, (2008), LANCET, 371, 1162 - 1163

• Cholesterol, statins, and mortality - Authors' reply

  Lewington S. et al, (2008), The Lancet, 371, 1162 - 1163

• Biomarkers of inflammation predict both vascular and non-vascular mortality in older men.

  Clarke R. et al, (2008), Eur Heart J, 29, 800 - 809

• Lipid fractions and survival in older men - Reply

  Clarke RJ. and Emberson JR., (2008), Archives of Internal Medicine, 168

• Ensuring trial validity by data quality assurance and diversification of monitoring methods.

  Baigent C. et al, (2008), Clin Trials, 5, 49 - 55

• Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths (vol 370, pg 1829, 2007)

  Lewington S. et al, (2008), LANCET, 372, 292 - 292

• Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.

  Prospective Studies Collaboration None. et al, (2007), Lancet, 370, 1829 - 1839

• Cholesterol fractions and apolipoprotiens are strong predictors of heart disease mortality in older men

  Clarke R. et al, (2007), EUROPEAN HEART JOURNAL, 28, 87 - 87

• Biomarkers of inflammation are stronger predictors than blood lipids for vascular and non-vascular mortality in old age

  Clarke R. et al, (2007), EUROPEAN HEART JOURNAL, 28, 631 - 631

• Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men.

  Clarke R. et al, (2007), Arch Intern Med, 167, 1373 - 1378

• A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spots.

  Mafham MM. et al, (2007), Nephron Clin Pract, 106, c104 - c112

• Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.

  Kearney PM. et al, (2006), BMJ, 332, 1302 - 1308

• Effects of older age on fibrin D-dimer, C-reactive protein, and other hemostatic and inflammatory variables in men aged 60-79 years.

  Rumley A. et al, (2006), J Thromb Haemost, 4, 982 - 987

• Cohort profile: the Mexico City Prospective Study.

  Tapia-Conyer R. et al, (2006), Int J Epidemiol, 35, 243 - 249

• Effect of alcohol on risk of coronary heart disease and stroke: causality, bias, or a bit of both?

  Emberson JR. and Bennett DA., (2006), Vasc Health Risk Manag, 2, 239 - 249

• Commentary: over-correction for regression dilution bias? Not for blood pressure vs coronary heart disease.

  Morris RW. and Emberson JR., (2005), Int J Epidemiol, 34, 1368 - 1369

• N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study

  Emberson J. et al, (2005), CIRCULATION, 112, U867 - U867

• N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study

  Emberson J. et al, (2005), EUROPEAN HEART JOURNAL, 26, 337 - 337

• Lifestyle and cardiovascular disease in middle-aged British men: the effect of adjusting for within-person variation.

  Emberson JR. et al, (2005), Eur Heart J, 26, 1774 - 1782

• Early experiences and their relationship to maternal eating disorder symptoms, both lifetime and during pregnancy.

  Senior R. et al, (2005), Br J Psychiatry, 187, 268 - 273

• Prevalence of undiagnosed Type 2 diabetes and impaired fasting glucose in older British men and women.

  Thomas MC. et al, (2005), Diabet Med, 22, 789 - 793

• Alcohol intake in middle age and risk of cardiovascular disease and mortality: accounting for intake variation over time.

  Emberson JR. et al, (2005), Am J Epidemiol, 161, 856 - 863

• Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women.

  Emberson JR. et al, (2005), Heart, 91, 451 - 455

• A multi-centre cohort study of the physical health of 5-year-old children conceived after intracytoplasmic sperm injection, in vitro fertilization and natural conception.

  Bonduelle M. et al, (2005), Hum Reprod, 20, 413 - 419

• INTERHEART.

  McKee M. et al, (2005), Lancet, 365, 117 - 118

• INTERHEART.

  Whincup P. et al, (2005), Lancet, 365

• The number needed to treat (NNT) can be adjusted for bias when the outcome is measured with error.

  Marschner IC. et al, (2004), J Clin Epidemiol, 57, 1244 - 1252

• The challenge of secondary prevention for coronary heart disease in older patients: findings from the British Women's Heart and Health Study and the British Regional Heart Study.

  Lawlor DA. et al, (2004), Fam Pract, 21, 582 - 586

• Reducing social inequalities and the prevention of coronary heart disease.

  Emberson JR. et al, (2004), Int J Epidemiol, 33, 1152 - 1153

• Drs. Emberson and Whincup respond

  Emberson JR. and Whincup PH., (2004), Cardiology Review, 21

• Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement.

  Whincup PH. et al, (2004), BMJ, 329, 200 - 205

• Accounting for CHD risk: How much do major risk factors explain?

  Emberson JR. and Whincup PH., (2004), Cardiology Review, 21

• Social class differences in coronary heart disease in middle-aged British men: implications for prevention.

  Emberson JR. et al, (2004), Int J Epidemiol, 33, 289 - 296

• Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study.

  Emberson JR. et al, (2004), Eur J Cardiovasc Prev Rehabil, 11, 125 - 134

• Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease.

  Emberson J. et al, (2004), Eur Heart J, 25, 484 - 491

• Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study.

  Brindle P. et al, (2003), BMJ, 327

• North-south gradients in Britain for stroke and CHD: are they explained by the same factors?

  Morris RW. et al, (2003), Stroke, 34, 2604 - 2609

• Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias.

  Emberson JR. et al, (2003), Eur Heart J, 24, 1719 - 1726

• Is the association between parity and coronary heart disease due to biological effects of pregnancy or adverse lifestyle risk factors associated with child-rearing? Findings from the British Women's Heart and Health Study and the British Regional Heart Study.

  Lawlor DA. et al, (2003), Circulation, 107, 1260 - 1264

• Biochemical measures in a population-based study: effect of fasting duration and time of day.

  Emberson JR. et al, (2002), Ann Clin Biochem, 39, 493 - 501

• A randomized controlled trial of exercise and manipulative therapy for cervicogenic headache.

  Jull G. et al, (2002), Spine (Phila Pa 1976), 27, 1835 - 1843

• Low prevalence of lipid lowering drug use in older men with established coronary heart disease.

  Whincup PH. et al, (2002), Heart, 88, 25 - 29

• Standardized mortality ratios and fatal pulmonary embolism rates following total knee replacement: a cohort of 936 consecutive cases.

  Khan A. et al, (2002), J Knee Surg, 15, 219 - 222

• Dementia and statins.

  Ebrahim S. et al, (2001), Lancet, 357

• Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial

  Reid IR. et al, (2001), Lancet, 357, 509 - 512

• Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease.

  Reid IR. et al, (2001), Lancet, 357, 509 - 512

• Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.

  Tonkin AM. et al, (2000), Lancet, 356, 1871 - 1875

• Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)

  Staplin ND. et al, Clinical Journal of the American Society of Nephrology

• The effects of smoking in patients with chronic kidney disease: results from the Study of Heart and Renal Protection

  Emberson J. et al, American Journal of Kidney Diseases

• Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease

  Herrington W. et al, Hypertension

• Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the Study of Heart and Renal Protection

  Reith CA. et al, BMC Nephrology

• Diabetes and Cause-Specific Mortality in Mexico City

  Herrington W. et al, New England Journal of Medicine

• Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies

  Staplin ND. et al, BMC Cancer

• Adiposity and blood pressure in 110,000 Mexican adults

  Gnatiuc L. et al, Hypertension

• A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease

  Schlackow I. et al, Heart

Recent Publications

• Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.

  Mafham MM. et al, (2017), Nephrol Dial Transplant

• Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care.

  Hin H. et al, (2016), Osteoporos Int

• Are statins useful in patients with advanced chronic kidney disease? - Authors' reply.

  Herrington WG. et al, (2016), Lancet Diabetes Endocrinol, 4, 971 - 972

• Interpretation of the evidence for the efficacy and safety of statin therapy.

  Collins R. et al, (2016), Lancet (London, England)

• Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).

  Staplin N. et al, (2016), American Journal of Kidney Diseases, 68, 371 - 380